Duloxetine in the prevention of relapse of major depressive disorder: Double-blind placebo-controlled study

British Journal of Psychiatry

Volumn 188, Issue APR., 2006, Pages 346-353

  Perahia, David G ^a,b   Gilaberte, Inmaculada ^c   Wang, Fujun ^a   Wiltse, Curtis G ^a   Huckins, Stacy A ^a   Clemens, Jeffrey W ^a   Montgomery, Stuart A ^d   Montejo, Angel L ^e   Detke, Michael J ^f,g,h  

^a ELI LILLY AND COMPANY   (United States)

^b Gordon Hospital   (United Kingdom)

^c Medical Department   (Spain)

^d IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^e HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g MCLEAN HOSPITAL   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DULOXETINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NAUSEA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SOMNOLENCE; SUICIDE ATTEMPT; VOMITING; XEROSTOMIA;

EID: 33645654076     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.188.4.346     Document Type: Article

References (25)

1. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM-IV): Washington, DC: APA.
2. Bymaster, F. P., Dreshfield-Ahinad, L. J., Threlkeld, P.G., et al (2001) Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology, 25, 871-880.
3. DeLoadi, L. J., Higgins, M. S., Caplan, A. B., et al (1998) The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale. Anesthesia and Analgesia, 86, 102-106.
4. Detke, M. J., Lu, Y., Goldstein, D. J., et al (2002) Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. Journal of Psychiatric Research, 36, 383-390.
5. Fava, M. (2002) Somatic symptoms, depression, and antidepressant treatment. Journal of Clinical Psychiatry, 63, 305-307.
6. Fava, M., Schmidt, M. E., Zhang, S., et al (2002) Treatment approaches to major depressive disorder relapse. Part 2. Reinitiation of antidepressant treatment. Psychotherapy and Psychosomatics, 71, 195-199.
7. Geddes, J. R., Carney, S. M., Davies, C., et al (2003) Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet, 361, 653-661.
8. Greenberg, P. E., Leong, S. A., Birnbaum, H. G., et al (2003) The economic burden of depression with painful symptoms. Journal of Clinical Psychiatry, 64, 17-23.
9. Guy, W. (1976) ECDEU Assessment Manual for Psychopharmacology, Revised. Rockville, MD: National Institute of Mental Health, Psychopharmacology Research Branch.
10. Hamilton, M. (1960) A rating scale for depression. journal of Neurology, Neurosurgery and Psychiatry, 26, 56-62.
11. Kellner, R. A. (1987) A symptom questionnaire. Journal of Clinical Psychiatry 48, 268-274.
12. McKenna, S. P. & Hunt, S. M. (1992) A new measure of quality of life in depression: testing the reliability and construct validity of the QLDS. Health Policy, 22, 321-330.
13. Hirschfeld, R. M. A. (2001) Clinical importance of long-term antidepressant treatment. British Journal of Psychiatry, 179 (suppl. 42), S4-S8.
14. Mallinckrodt, C. H., Clark, W. S. & David, S. R. (2001) Type I error rates from mixed-effects model repeated measures compared with fixed-effects ANOVA with missing values imputed via LDCF. Drug Information Journal. 35, 1215-1225.
15. Melfi, C. A., Chawla, A. J., Croghan, T.W., et al (1998) The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Archives of General Psychiatry. 55, 1128-1132.
16. Montgomery, S. A., Rasmussen, J. G. & Tanghoj, P. (1993) A 24-week study of 20 mg citalopram, 40 mg crtalopram, and placebo in the prevention of relapse of major depression. International Clinical Psychopharmacology, 8, 181-186.
17. Nemeroff, C. B., Schatzberg, A. F., Goldstein, D. J., et al (2002) Duloxetine for the treatment of major depressive disorder. Psychopharmacology Bulletin, 36, 106-132.
18. Rapaport, M. H., Bose, A. & Zheng, H. (2004) Escitalopram continuation treatment prevents relapse of depressive episodes. Journal of Clinical Psychiatry, 65, 44-49.
19. Rosenbaum, J. F., Fava, M., Hoog, S. U, et al (1998) Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biological Psychiatry. 44, 77-87.
20. Schmidt, H. E., Fava, M., Zhang, S., et al (2002) Treatment approaches to major depressive disorder relapse. Part I: Dose increase. Psychotherapy and Psychosomatics, 71, 190-194.
21. Segal, Z., Pearson, J. & Thase, M. E. (2003) Challenges in preventing relapse in major depression. Report of a National Institute of Mental Health Workshop on state of the science of relapse prevention in major depression. Journal of Affective Disorders, 77, 97-108.
22. Sheehan, D. V., Lecrubier, Y., Sheehan, K. H., et al (1998) The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry, 59 (suppl. 20), 22-33.
23. Thase, M. E., Entsuah, A. R. & Rudolph, R. L. (2001) Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. British. Journal of Psychiatry, 178, 234-241.
24. Thomas, C. M. & Morris, S. (2003) Cost of depression among adults in England in 2000. British Journal of Psychiatry, 183, 514-519.
25. World Health Organization (1989) Pharmacotherapy of depressive disorders: consensus statement. WHO Mental Health Collaborating Centres. Journal of Affective Disorders, 17, 197-198.